FOXO4-DRI 10 mg

Steroids Dragon Pharma Peptides

$70.00

Dragon Pharma FOXO4-DRI 10 mg – Experimental Senolytic Peptide for Senescence Research

✔ Selective senescent cell clearance ✔ FOXO4-p53 pathway inhibitor ✔ Studied for anti-aging mechanisms ✔ USA domestic shipping available

Dragon Pharma FOXO4-DRI 10 mg is an experimental senolytic peptide designed to selectively target and eliminate senescent cells, commonly referred to as "zombie" cells. This peptide functions by blocking the interaction between the FOXO4 and p53 proteins, a mechanism that has been investigated in preclinical studies for its potential to reduce age-related markers and improve physical function.

Each vial contains 10 mg of lyophilized FOXO4-DRI in a 2 mL format, requiring reconstitution with bacteriostatic water before use. FOXO4-DRI represents a targeted research tool for investigating cellular senescence, aging processes, and potential therapeutic interventions. For related research compounds, explore our peptides category and specifically Epitalon 50 mg for complementary longevity research applications.

What Makes FOXO4-DRI Valuable in Research?

FOXO4-DRI is a rationally designed peptide that specifically disrupts the FOXO4-p53 interaction, which is critical for senescent cell survival. By interfering with this protein-protein interaction, FOXO4-DRI triggers apoptosis selectively in senescent cells while leaving healthy cells unaffected. This targeted approach has demonstrated promising results in preclinical mouse models, showing reduced senescence markers and improved physical performance.

Researchers value FOXO4-DRI for its specificity and the mechanistic insights it provides into cellular senescence pathways. Its ability to selectively clear senescent cells makes it a valuable tool for investigating the role of senescence in aging, tissue dysfunction, and age-related diseases. For investigators exploring cellular protection mechanisms, SS-31 50 mg offers complementary research avenues in mitochondrial function and cellular health.

Current scientific literature on FOXO4-DRI and senolytic research can be accessed through the PubMed database, where researchers can review peer-reviewed studies on its biological activity and experimental applications.

Key Research Applications for Dragon Pharma FOXO4-DRI

✔ Investigation of cellular senescence mechanisms
✔ Evaluation of senolytic activity in various tissue types
✔ Research on aging and age-related pathologies
✔ Studies of tissue regeneration following senescence clearance
✔ Preclinical models of physical function and recovery

For Research Purposes Only

FOXO4-DRI 10 mg is intended for research use only and is not approved for human consumption. Proper handling, reconstitution, and experimental protocols are essential for reliable results. For studies on regenerative peptides, BPC 157 provides additional research avenues in tissue repair mechanisms.

Dispatched within 24 hours in plain, discreet packaging.

Additional Information

Categories:

Steroids

Brand: Dragon Pharma

Manufacturer: Dragon Pharma

Dosage Info: <div class="tab-pane fade" id="offer-tabbody--dosage-and-usage" role="tabpanel"> <section class="tab-panel" id="panel-usage"> <h2>Dosage & Usage Guidelines</h2> <div class="info-card warning"> <p><strong>For research and laboratory use only.</strong> Dragon Pharma FOXO4-DRI 10 mg is an experimental senolytic peptide. Proper reconstitution, handling, and experimental design are essential for obtaining reliable data.</p> </div> <h3>Reconstitution Protocol</h3> <ul class="usage-highlights"> <li>✔ Use sterile bacteriostatic water for injection</li> <li>✔ Add appropriate volume to achieve desired concentration</li> <li>✔ Swirl gently to dissolve – do not shake vigorously</li> <li>✔ Store reconstituted solution at 2–8°C</li> </ul> <p>Reconstitute the lyophilized powder using bacteriostatic water to a concentration suitable for your research protocol. The 10 mg format allows for flexible dosing across a range of experimental models. Always use aseptic technique during preparation to maintain peptide integrity.</p> <h3>Typical Research Parameters</h3> <p>In research settings, FOXO4-DRI is typically administered via subcutaneous or intraperitoneal injection. Dosing schedules and concentrations vary widely depending on the experimental design, animal model, and specific research objectives.</p> <ul> <li>✔ Commonly used in senescence clearance studies</li> <li>✔ Often combined with tissue analysis and biomarker evaluation</li> <li>✔ Used to investigate aging mechanisms and physical function</li> <li>✔ Research models include aged mice and senescence-accelerated models</li> </ul> <h3>Factors to Consider in Research Protocols</h3> <ul> <li>Specific targeting of senescent cells requires careful dose optimization</li> <li>Reconstitution stability is limited; prepare fresh solutions for each use</li> <li>Individual variation in response may be observed across subjects</li> <li>Storage conditions significantly impact peptide stability</li> </ul> <div class="info-card"> <p><strong>Research note:</strong> FOXO4-DRI selectively induces apoptosis in senescent cells by disrupting the FOXO4-p53 interaction. This targeted mechanism provides a unique opportunity to investigate the contribution of cellular senescence to aging and age-related pathologies in preclinical models.</p> </div> </section> </div>

Reviews:

(0 customer reviews)